Suppr超能文献

雄激素剥夺诱导的衰老促进雄激素难治性前列腺癌细胞的生长。

Androgen deprivation-induced senescence promotes outgrowth of androgen-refractory prostate cancer cells.

机构信息

Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, United States of America.

出版信息

PLoS One. 2013 Jun 28;8(6):e68003. doi: 10.1371/journal.pone.0068003. Print 2013.

Abstract

Androgen deprivation (AD) is an effective method for initially suppressing prostate cancer (PC) progression. However, androgen-refractory PC cells inevitably emerge from the androgen-responsive tumor, leading to incurable disease. Recent studies have shown AD induces cellular senescence, a phenomenon that is cell-autonomously tumor-suppressive but which confers tumor-promoting adaptations that can facilitate the advent of senescence-resistant malignant cell populations. Because androgen-refractory PC cells emerge clonally from the originally androgen-responsive tumor, we sought to investigate whether AD-induced senescence (ADIS) affects acquisition of androgen-refractory behavior in androgen-responsive LNCaP and LAPC4 prostate cancer cells. We find that repeated exposure of these androgen-responsive cells to senescence-inducing stimuli via cyclic AD leads to the rapid emergence of ADIS-resistant, androgen-refractory cells from the bulk senescent cell population. Our results show that the ADIS phenotype is associated with tumor-promoting traits, notably chemoresistance and enhanced pro-survival mechanisms such as inhibition of p53-mediated cell death, which encourage persistence of the senescent cells. We further find that pharmacologic enforcement of p53/Bax activation via Nutlin-3 prior to establishment of ADIS is required to overcome the associated pro-survival response and preferentially trigger pervasive cell death instead of senescence during AD. Thus our study demonstrates that ADIS promotes outgrowth of androgen-refractory PC cells and is consequently a suboptimal tumor-suppressor response to AD.

摘要

去势治疗(AD)是抑制前列腺癌(PC)进展的有效方法。然而,雄激素抵抗性 PC 细胞不可避免地从雄激素反应性肿瘤中出现,导致无法治愈的疾病。最近的研究表明,AD 诱导细胞衰老,这是一种细胞自主的肿瘤抑制现象,但会赋予肿瘤促进适应性,从而促进衰老抵抗性恶性细胞群体的出现。因为雄激素抵抗性 PC 细胞从最初的雄激素反应性肿瘤中克隆出现,我们试图研究 AD 诱导的衰老(ADIS)是否会影响雄激素反应性 LNCaP 和 LAPC4 前列腺癌细胞获得雄激素抵抗行为。我们发现,这些雄激素反应性细胞反复暴露于通过周期性 AD 诱导的衰老刺激下,会导致大量衰老细胞群体中迅速出现 ADIS 抗性、雄激素抵抗性细胞。我们的结果表明,ADIS 表型与促进肿瘤的特征相关,特别是化疗耐药性和增强的生存机制,如抑制 p53 介导的细胞死亡,这鼓励衰老细胞的持续存在。我们进一步发现,在建立 ADIS 之前,通过 Nutlin-3 强制激活 p53/Bax,是克服相关生存反应并在 AD 期间优先引发广泛细胞死亡而不是衰老所必需的。因此,我们的研究表明,ADIS 促进了雄激素抵抗性 PC 细胞的生长,因此是 AD 的一种次优的肿瘤抑制反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68ce/3695935/73add858a213/pone.0068003.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验